To recover your password please fill in your email address
Please fill in below form to create an account with us
CRESTONE is a multicenter open-label, phase 2 trial of seribantumab in patients with NRG1 gene fusion-positive, advanced solid tumours. The Australian patient subset, known as MoST CRESTONE, will be identified through the MoST program.
|
Trial Summary: |
To assess the clinical activity of seribantumab in patients with NRG1 fusion positive locally advanced or metastatic solid tumours. |
|
Supported By: |
Elevation Oncology Inc. |
|
Eligibility: |
Adults with recurrent, locally advanced or metastatic solid tumours which harbour the NRG1 gene fusion and have had received prior standard treatment. |
|
Registration ID: |
NCT04383210 |
|
Participation: |
USA, Canada, Australia |
|
Australian Lead Group: |
N/A |
|
Status: |
Closed |
|
Activation Date: |
20 November 2021 |
|
Chairs: |
Dr Subotheni Thavaneswaran |
|
Contact: |